Novo Nordisk Up 2%, Continuing Strong Yearly Performance

By Naomi Wentworth • Tuesday, June 06 10:06 • Permanent Link

Novo Nordisk logged a 2.1% change during today's morning session, and is now trading at a price of $161.15 per share. The S&P 500 index moved -0.0%. NVO's trading volume is 289,591 compared to the stock's average volume of 1,444,680.

Novo Nordisk trades -8.84% away from its average analyst target price of $176.77 per share. The 4 analysts following the stock have set target prices ranging from $156.94 to $195.04, and on average have given Novo Nordisk a rating of buy.

If you are considering an investment in NVO, you'll want to know the following:

Novo Nordisk's current price is 319.9% above its Graham number of $38.38, which implies that at its current valuation it does not offer a margin of safety
Novo Nordisk has moved 36.2% over the last year, and the S&P 500 logged a change of 2.7%
Based on its trailing earnings per share of 3.87, Novo Nordisk has a trailing 12 month Price to Earnings (P/E) ratio of 41.6 while the S&P 500 average is 15.97
NVO has a forward P/E ratio of 28.7 based on its forward 12 month price to earnings (EPS) of $5.62 per share
The company has a price to earnings growth (PEG) ratio of 78.24 — a number near or below 1 signifying that Novo Nordisk is fairly valued compared to its estimated growth potential
Its Price to Book (P/B) ratio is 36.31 compared to its sector average of 4.16
Novo Nordisk, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide.
Based in Bagsvaerd, the company has 57,089 full time employees and a market cap of $361.48 Billion.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.